Kuttiappan Anitha
Research Subjects
Kuttiappan Anitha has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Balakrishnan Sadasivam
All India Institute of Medical Sciences, Bhopal, India
2 shared publications - Krishna Chaitanya Amerneni
University of Arizona, Tucson, USA
2 shared publications - Mohan Krishna Ghanta
Department of Pharmacology, MVJ Medical College and Research Hospital
2 shared publications - R. Padmavathi
Mediciti Institute of Medical Sciences, Hyderabad, India
2 shared publications Santenna Chenchula
All India Institute of Medical Sciences (AIIMS)
2 shared publications- Santenna Chenchula
Department of Pharmacology, AIIMS Bhopal, India
2 shared publications
Latest Publications
- 27 April 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (5) , 2843-2854
Metformin for knee osteoarthritis in overweight and obese adults: a systematic review and meta-analysis of efficacy, safety, and disease-modifying anti-inflammatory potential
Introduction Knee osteoarthritis (OA) is a degenerative joint disease involving progressive cartilage loss, subchondral bone remodelling, and inflammation. This systematic review and meta-analysis aimed to assess the efficacy and safety of metformin in reducing knee pain and adverse events among overweight and obese adults with symptomatic knee OA. Methods We systematically searched PubMed, Scopus, and CENTRAL from inception to August 2025. Eligible randomised controlled trials (RCTs) compared oral metformin with placebo or standard care in adults with BMI ≥ 25 kg/m2 and symptomatic knee OA. Primary outcomes were pain reduction (standardised mean difference) and gastrointestinal (GI) adverse events (risk ratio). Risk of bias was assessed using the Cochrane ROB 2 tool, publication bias using the Doi plot and LFK index, and evidence certainty using the GRADE-pro approach. Results Seven studies (n = 1237) were included: six RCTs and one observational study. Meta-analysis included only RCTs. Metformin significantly reduced knee pain compared with controls (SMD: − 0.42; 95% CI: − 0.62 to − 0.21; I2 = 95%). Sensitivity analysis excluding an outlier study produced a consistent effect (SMD: − 0.54; 95% CI: − 0.74 to − 0.33; I2 = 91%). Based on GRADE assessment, the certainty of evidence for pain reduction was high. Metformin increased the risk of mild, non-serious gastrointestinal adverse events (RR: 1.97; 95% CI: 1.06–3.67; I2 = 0%), with moderate certainty due to imprecision. Conclusions Metformin provides clinically meaningful pain reduction in overweight/obese adults with knee OA but increases mild, non-serious gastrointestinal adverse events. These findings support metformin as a promising disease-modifying therapy for metabolically complex OA phenotypes; longer-duration trials with structural endpoints are warranted.
- 27 April 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (5) , 2843-2854
Metformin for knee osteoarthritis in overweight and obese adults: a systematic review and meta-analysis of efficacy, safety, and disease-modifying anti-inflammatory potential
Introduction Knee osteoarthritis (OA) is a degenerative joint disease involving progressive cartilage loss, subchondral bone remodelling, and inflammation. This systematic review and meta-analysis aimed to assess the efficacy and safety of metformin in reducing knee pain and adverse events among overweight and obese adults with symptomatic knee OA. Methods We systematically searched PubMed, Scopus, and CENTRAL from inception to August 2025. Eligible randomised controlled trials (RCTs) compared oral metformin with placebo or standard care in adults with BMI ≥ 25 kg/m2 and symptomatic knee OA. Primary outcomes were pain reduction (standardised mean difference) and gastrointestinal (GI) adverse events (risk ratio). Risk of bias was assessed using the Cochrane ROB 2 tool, publication bias using the Doi plot and LFK index, and evidence certainty using the GRADE-pro approach. Results Seven studies (n = 1237) were included: six RCTs and one observational study. Meta-analysis included only RCTs. Metformin significantly reduced knee pain compared with controls (SMD: − 0.42; 95% CI: − 0.62 to − 0.21; I2 = 95%). Sensitivity analysis excluding an outlier study produced a consistent effect (SMD: − 0.54; 95% CI: − 0.74 to − 0.33; I2 = 91%). Based on GRADE assessment, the certainty of evidence for pain reduction was high. Metformin increased the risk of mild, non-serious gastrointestinal adverse events (RR: 1.97; 95% CI: 1.06–3.67; I2 = 0%), with moderate certainty due to imprecision. Conclusions Metformin provides clinically meaningful pain reduction in overweight/obese adults with knee OA but increases mild, non-serious gastrointestinal adverse events. These findings support metformin as a promising disease-modifying therapy for metabolically complex OA phenotypes; longer-duration trials with structural endpoints are warranted.
- 20 March 2024
- Published by Springer Nature
- p. 45-64
Revolutionizing Lung Cancer Treatment: Recent Breakthroughs in Immunotherapy
- 20 March 2024
- Published by Springer Nature
- p. 45-64
Revolutionizing Lung Cancer Treatment: Recent Breakthroughs in Immunotherapy
- 1 January 2024
- Published by Springer Nature
- p. 103-144
Combination Therapies for the Management of Cancer Immunotherapy
- 1 January 2024
- Published by Springer Nature
- p. 103-144
Combination Therapies for the Management of Cancer Immunotherapy